Rational drug design and synthesis of a selective ε opioid receptor antagonist on the basis of the accessory site concept

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 16, 2004, Pages 4241-4243

  Fujii, Hideaki ^a   Narita, Minoru ^b   Mizoguchi, Hirokazu ^b   Hirokawa, Junichi ^a   Kawai, Koji ^a   Tanaka, Toshiaki ^a   Tseng, Leon F ^b   Nagase, Hiroshi ^a  

^a TORAY INDUSTRIES INC   (Japan)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Opioid receptor antagonist; Accessory site; Putative opioid receptor

Indexed keywords

17 (CYCLOPROPYLMETHYL) 4,5ALPHA EPOXY 6BETA,21 EPOXYMETHANO 3 HYDROXY 6,4 ETHENOMORPHINAN 7ALPHA (N PHENETHYL)CARBOXAMIDE; BETA ENDORPHIN; EPSILON OPIATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; INJECTION SITE; NONHUMAN; RAT; TAIL FLICK TEST; VAS DEFERENS;

ANIMALS; BETA-ENDORPHIN; DRUG DESIGN; MALE; MORPHINANS; RATS; RECEPTORS, OPIOID; VAS DEFERENS;

EID: 3142773369     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.06.004     Document Type: Article

References (20)

1. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., Hamon M. Pharmacol. Rev. 48:1996;567
2. Tseng L.F. Tseng L.F. The Pharmacology of Opioid Peptides. 1995;249-269 Harwood Academic, Singapore
3. Narita M., Tseng L.F. Jpn. J. Pharmacol. 76:1998;233
4. Tseng L.F. Trends. Pharmacol. Sci. 22:2001;623
5. Portoghese P.S., Sultana M., Nagase H., Takemori A.E. J. Med. Chem. 31:1988;281
6. Portoghese P.S., Nagase H., Lipkowski A.W., Larson D.L., Takemori A.E. J. Med. Chem. 31:1988;836
7. Fujii, H.; Narita, M.; Mizoguchi, H.; Murachi, M.; Tanaka, T.; Kawai, K.; Tseng, L. F.; Nagase, H. Bioorg. Med. Chem. 2004, 12, in press
8. Nogrady T. Nogrady T. Medicinal Chemistry, A Biochemical Approach. 1985;68-69 Oxford University Press, New York
9. Nagase H., Hayakawa J., Kawamura K., Kawai K., Takezawa Y., Matsuura H., Tajima C., Endo T. Chem. Pharm. Bull. 46:1998;366
10. Nagase H., Kawai K., Hayakawa J., Wakita H., Mizusuna A., Matsuura H., Tajima C., Takezawa Y., Endo T. Chem. Pharm. Bull. 46:1998;1695
11. Nagase H., Yajima Y., Fujii H., Kawamura K., Narita M., Kamei J., Suzuki T. Life Sci. 68:2001;2227
12. Fujii H., Kawai K., Kawamura K., Mizusuna A., Onoda Y., Murachi M., Tanaka T., Endo H., Nagase H. Drug Des. Discov. 17:2001;325
13. Fülöp F., Bernáth G. J. Chem. Soc., Perkin Trans. 1. 1984;2043
14. 3H: C, 63.66; H, 6.55; N, 4.40; S, 5.28. Found: C, 63.66; H, 6.55; N, 4.57; S, 5.46
15. Smith J.A.M., Leslie F.M. Handbooks of Experimental Pharmacology. Hertz A. Opioids I. Vol. 104/I:1993;62-78 Springer, Berlin, Heidelberg
16. Wuster M., Schulz R., Herz A. Neurosci. Lett. 15:1979;193
17. 50 ratio-1)}
18. Tesng L.F., Li C.H. Int. J. Pept. Res. 27:1986;394
19. Suh H.H., Tseng L.F., Li C.H. Neuropharmacology. 27:1988;957
20. Mizoguchi H., Spaulding A., Leitermann R., Wu H.E., Nagase H., Tseng L.F. J. Pharmacol. Exp. Ther. 306:2003;394